Advances in Biomarker Discovery for Early Ovarian Cancer Diagnosis
10 affiliations
- 1Division of Anatomy, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland
- 2University College London Medical School, London WC1E 6DE, UK
- 3Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland
- 4Prestage Department of Poultry Science, North Carolina State University, Raleigh, NC 27695, USA
- 5Physiology Graduate Faculty, North Carolina State University, Raleigh, NC 27695, USA
- 6Institute of Medical Sciences, Adam Mickiewicz University, 64-920 Piła, Poland
- 7Department of Human Biology, Faculty of Physiotherapy, Wroclaw, University of Health and Sport Sciences, 51-612 Wroclaw, Poland
- 8Center of Assisted Reproduction, Department of Obstetrics and Gynecology, University Hospital and Masaryk University, 625 00 Brno, Czech Republic
- 9Department of Veterinary Surgery, Institute of Veterinary Medicine, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland
- 10Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, 8091 Zurich, Switzerland
Abstract
Ovarian cancer is one of the deadliest gynecological cancers worldwide. One promising therapeutic approach is the use of combined biomarkers. The Risk of Ovarian Malignancy Algorithm (ROMA) which combines CA125 with Human Epididymal Protein 4 (HE4) is an example of combining biomarkers to gain an optimal predictive outcome. Tumor Protein p53 (TP53) is a transcription factor with tumor suppressor properties. Mutations in TP53 constitute the most frequent genetic alterations observed in ovarian cancer. In contrast to conventional markers such as CA125, circulating tumor DNA (ctDNA) provides information about tumor mutations and insights into treatment response. Analysis of ctDNA enables the identification of tumor-associated mutations. Non-coding RNAs (ncRNAs) also influence cellular processes and act as effectors in oncogenic pathways by binding to RNA or proteins. One effector is Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), whose increased expression is associated with an aggressive tumor phenotype. MicroRNAs (miRNAs) are crucial in regulating the expression of genes associated with ovarian cancer development and progression. Exosomes carrying various molecules, including miRNAs and lncRNAs, contribute to ovarian cancer progression. Adipocytokines play an important role in the regulation of metabolic and inflammatory processes. Despite their diagnostic potential, the identified biomarkers require further validation.
Related
- Ovarian Cyst Fluid as a Resource for Diagnostic and Prognostic Biomarker Discovery in Ovarian Lesions.
- Epidemiology, Symptoms, Risk factors, Classification, Staging, and Diagnosis of Ovarian Cancer
- Circulating miRNAs and Multivariate Biomarker Signatures in Ovarian Cancer: A Systematic Review
- Knowledge attitudes and practices of healthcare professionals regarding magnetic resonance imaging for ovarian cancer diagnosis
- Molecular Biomarker Testing in Kidney Cancer: Integrating Diagnosis, Prediction, and Emerging Renal Tumor Entities
BibTeX
@article{niebora2026advances,
title = {{Advances in Biomarker Discovery for Early Ovarian Cancer Diagnosis}},
author = {Julia Niebora and Julia Spaczyńska and Aleksandra Partyńska and Natalia Penciak and Dominika Domagała and Krzysztof Data and Paul Mozdziak and Artur Bryja and Piotr P. Chmielewski and Paweł Dąbrowski and Teresa Wysocka and Maciej Zabel and Marzenna Podhorska-Okołów and Piotr Dzięgiel and Bartosz Kempisty and Ievgeniia Kocherova},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15211940},
url = {https://www.mdpi.com/2073-4409/15/21/1940},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Advances in Biomarker Discovery for Early Ovarian Cancer Diagnosis
AU - Julia Niebora
AU - Julia Spaczyńska
AU - Aleksandra Partyńska
AU - Natalia Penciak
AU - Dominika Domagała
AU - Krzysztof Data
AU - Paul Mozdziak
AU - Artur Bryja
AU - Piotr P. Chmielewski
AU - Paweł Dąbrowski
AU - Teresa Wysocka
AU - Maciej Zabel
AU - Marzenna Podhorska-Okołów
AU - Piotr Dzięgiel
AU - Bartosz Kempisty
AU - Ievgeniia Kocherova
PY - 2026
DA - 2026/10/25
JO - Cells
DO - 10.3390/cells15211940
UR - https://www.mdpi.com/2073-4409/15/21/1940
AB - Ovarian cancer is one of the deadliest gynecological cancers worldwide. One promising therapeutic approach is the use of combined biomarkers. The Risk of Ovarian Malignancy Algorithm (ROMA) which combines CA125 with Human Epididymal Protein 4 (HE4) is an example of combining biomarkers to gain an optimal predictive outcome. Tumor Protein p53 (TP53) is a transcription factor with tumor suppressor properties. Mutations in TP53 constitute the most frequent genetic alterations observed in ovarian cancer. In contrast to conventional markers such as CA125, circulating tumor DNA (ctDNA) provides information about tumor mutations and insights into treatment response. Analysis of ctDNA enables the identification of tumor-associated mutations. Non-coding RNAs (ncRNAs) also influence cellular processes and act as effectors in oncogenic pathways by binding to RNA or proteins. One effector is Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), whose increased expression is associated with an aggressive tumor phenotype. MicroRNAs (miRNAs) are crucial in regulating the expression of genes associated with ovarian cancer development and progression. Exosomes carrying various molecules, including miRNAs and lncRNAs, contribute to ovarian cancer progression. Adipocytokines play an important role in the regulation of metabolic and inflammatory processes. Despite their diagnostic potential, the identified biomarkers require further validation.
SN - 2073-4409
ER -